Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Key Points. Treatment with KMP vs VMP in transplant-ineligible NDMM patients resulted in similar PFS, with no statistically significant differences.There w
www.bloodjournal.org